-+ 0.00%
-+ 0.00%
-+ 0.00%

*Transcode Therapeutics: Lead Program TTX-MC138 Is in Phase 2a Clinical Development for ctDNA-positive Colorectal Cancer Following Curative-Intent Treatment >RNAZ

Dow Jones·10/28/2026 20:36:00

Please log in to view news